Your browser doesn't support javascript.
loading
Is host heparanase required for the rapid spread of heparan sulfate binding viruses?
Khanna, Mayank; Ranasinghe, Charani; Browne, Anna M; Li, Jin-Ping; Vlodavsky, Israel; Parish, Christopher R.
Afiliação
  • Khanna M; Cancer & Vascular Biology Group, ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia; Molecular Mucosal Vaccine Immunology Group, Department of Immunology and Infectious Diseases, The John Curtin
  • Ranasinghe C; Molecular Mucosal Vaccine Immunology Group, Department of Immunology and Infectious Diseases, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Browne AM; Cancer & Vascular Biology Group, ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
  • Li JP; Department of Medical Biochemistry and Microbiology, Uppsala Universitet, Uppsala, Sweden.
  • Vlodavsky I; Cancer and Vascular Biology Research Center, Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
  • Parish CR; Cancer & Vascular Biology Group, ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
Virology ; 529: 1-6, 2019 03.
Article em En | MEDLINE | ID: mdl-30622027
ABSTRACT
Vaccinia virus (VACV), like many other viruses, binds to cell surface heparan sulfate (HS) prior to infecting cells. Since HS is ubiquitously expressed extracellularly, it seemed likely that VACV-HS interaction may impede virus spread, with host heparanase, the only known mammalian endoglycosidase that can degrade HS, potentially overcoming this problem. In support of this hypothesis, we found that, compared to wild type, mice deficient in heparanase showed a 1-3 days delay in the spread of VACV to distant organs, such as ovaries, following intranasal inoculation, or to ovaries and spleen following intramuscular inoculation. These delays in spread occurred despite heparanase deficiency having no effect on VACV replication at inoculation sites. Subsequent in vitro studies revealed that heparanase treatment released VACV from HS expressing, but not HS deficient, infected cell monolayers. Collectively these data suggest that VACV relies on host heparanase to degrade HS in order to spread to distant sites.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vaccinia virus / Glucuronidase / Heparitina Sulfato Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vaccinia virus / Glucuronidase / Heparitina Sulfato Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article